First and only oral therapy approved for mild, moderate, and severe plaque psoriasis, and active PsA SEE THE DATA
3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Read more
*Estimates of patients treated reflect global data since launch (Apr 2014-Aug 2022; US=approximately 60% of data). Calculations based on observed drug utilization parameters and number of units distributed. Utilization patterns change over time to best represent current markets.
FDA, U.S. Food and Drug Administration; PsA, psoriatic arthritis; TB, tuberculosis.
References: 1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc. 2. Data on file, Amgen Inc. 3. Otezla® (apremilast) FDA approval letter. March 21, 2014.
48 years old
Insurance Account Manager
Hypothetical patient
40 years old
Electrician
Hypothetical patient
37 years old
Teacher and Coach
Hypothetical patient
32 years old
Restaurant Manager
Hypothetical patient
45 years old
Executive Assistant
Hypothetical patient
48 years old
Journalist
Hypothetical patient
37 years old
Chef
Hypothetical patient
BSA, body surface area; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for the full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for
phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
References: 1. Aldredge LM, Higham RC. JDNA. 2018;10(4):189-197. 2. Kaplan D. Hetherington J, Lucas J, et al. J Dermatolog Treat. 2022;33(6):2844-2852. 3. Blakely K, Gooderham M. Psoriasis (Auckl). 2016;66:33-40. 4. Van Voorhees AS, Feldman SR, Lebwohl MG, et al. psoriasis.org/the-pocket-guide. Accessed December 8, 2022. 5. Kimmel GW, Lebwohl M. Springer. 2018:1-16. 6. Husni ME, Fernandez A, Hauber B, et al. Arthritis Res Ther. 2018;20(1):102. 7. Cutolo M, Myerson GE, Fleischmann RM, et al. J Rheumatol. 2016;43(9):1724-1734. 8. Kavanaugh A, Helliwell P, Ritchlin CT. Rheumatol Ther. 2016;3(1):91-102. 9. Sakkas LI, Alexiou I, Simopoulou T, et al. Semin Arthritis Rheum. 2013;43(3):325-334. 10. Barnes CG. In: Yazici Y, Yazici H, eds. Behcet's Synrdone. Springer; 20210:7-33. 11. Alpsoy E, Akman. A. Therapy. 2016;3(1)139-151. 12. Alpsoy E, Donmez L, Onder M, et al. Br J Dermatol. 2007;157(5);901-906.